NFKB1 and CD4+/CD56+ hematodermic neoplasm: Furthermore, BPDCN is characterized by constitutive activation of the NF-κB pathway, which has been established as a potential target for therapy through the use of NF-κB p65 inhibitors, as it has shown sensitivity to their action [119–122].